NCT05217498View on ClinicalTrials.gov

Combining Low Oxygen Therapy and an Adenosine A2a Receptor Antagonist to Improve Functional Mobility After Spinal Cord Injury

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

December 30, 2026

Study Completion Date

June 30, 2027

Conditions
Spinal Cord InjuriesMyelopathy
Interventions
DRUG

Istradefylline

Consume 20mg tablet of istradefylline for 28 consecutive days.

DEVICE

low oxygen therapy

Breath intermittent low oxygen 4 days/week over 2 consecutive weeks. Intermittent low oxygen consists of 15, 90-second episodes of breathing low oxygen at 10% oxygen with 60-second intervals at 21% oxygen.

Trial Locations (1)

02138

Spaulding Rehabilitation Hospital, Cambridge

All Listed Sponsors
lead

Randy Trumbower, PT, PhD

OTHER